Topics
Glioblastoma | Treatment | Clinical trials | Vaccines
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Vaccines
Galanis E, Dooley KE, Keith
Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ,
Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson
SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC,
Giannini C, Raghunathan A, Iankov ID, Parney IF.
Carcinoembryonic
antigen-expressing oncolytic measles virus derivative in recurrent
glioblastoma: a phase 1 trial.
Nat
Commun. 2024 Jan
12;15(1):493. doi:
10.1038/s41467-023-43076-7. PMID:
38216554. Interventional
study. ˍ
Muragaki
Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, Komori
T, Yokoo H, Matsutani M, Maebayashi K, Tanaka T, Yamaguchi S,
Kanamori M, Yamamoto T, Hanihara M, Arakawa Y, Sasayama T, Abe T,
Nakamura H, Mukasa A, Uzuka T, Nakajo K, Ohno T.
A
randomized, placebo-controlled phase III trial of an autologous,
formalin-fixed tumor vaccine for newly diagnosed glioblastoma:
trial protocol.
Jpn
J Clin Oncol.
2025 May 16:hyaf078. doi:
10.1093/jjco/hyaf078. PMID:
40377260. Interventional study protocol˰ ˍ
Bota DA, Piccioni DE, Duma CM, Kesari S, Carrillo JA, LaRocca RV,
Aiken RD, Taylor TH, Abedi M, Robles RM, Godding K, Keirstead HS,
Nistor GI, Dillman RO.
Phase 2 trial
of personal dendritic cell vaccines in newly diagnosed
glioblastoma: 3-year follow-up and correlations with survival.
Hum
Vaccin Immunother. 2025 Sep 12;21(1):2556591. doi:
10.1080/21645515.2025.2556591. PMID:
40938661. Interventional study. ˍ
Jha R, Spanehl L, Chen JA, Gessler FA, Arnaout O, Valdes PA, Choi
BD, Peruzzi PP, Bernstock JD, Chiocca EA.
Translational
advancements in tumor vaccine therapies for glioblastomas.
Neurooncol
Adv. 2025 Sep 9;7(Suppl 4):iv72-iv83. doi:
10.1093/noajnl/vdaf051. PMID:
40933034. Review. ˍ
Chen HC, Wong ET, Sarangi S, Elinzano H, Kuburich NA, Mani SA, Ali
R, Cielo D, Svokos KA, Sampath P, Malik AN, Lee CK, Doberstein CE,
Lawler SE, Seyhan A, El-Deiry WS, Chen CC.
Tumor
antigen only (TAO) vaccine platforms for glioblastoma
therapeutics: a systematic review of evidence from clinical
trials.
EClinicalMedicine.
2026 Feb 26;93:103774. doi:
10.1016/j.eclinm.2026.103774. PMID:
41783089. ˍ
Kunz EM, Foster DT, Durrani A, Kioutchoukova IP, Thakkar R,
Davidson C, Foreman M, Lucke-Wold B.
Active
immunization strategies in glioblastoma - clinical outcomes and
effect modifiers for dendritic vaccines and adoptive cell
therapies: a systematic review.
J
Clin Neurosci. 2026 Mar 14;148:111983. doi:
10.1016/j.jocn.2026.111983. PMID:
41833230˰ ˍ
Georges JF, Clay C, Amin S, Goralczyk A, Mossop C, Bilbao CJ,
Valeri A, Ifrach J, Zaher M, Colman L, Kohler L, Schumann EH, Vu
M, Burns BA, Trivedi A, Liu W, Namekar M, Hofferek CJ, Ernste KJ,
Bisht N, Vazquez-Perez J, Oyewole-Said D, Amanya SB, Rodriguez V,
Kraushaar DC, Okoebor D, Bellayr I, Hartenbach J, Halpert MM, Duus
EM, Aguilar LK, Hsu SH, Zhu JJ, Zvavanjanja RC, Bai Y, Kang SW,
Jang HJ, Lee HS, Garg R, Esquenazi Y, Tandon N, Turtz A, Konduri
V, Decker WK.
Phase I Clinical Study
of DOC1021 (dubodencel) for Adjuvant Immunotherapy of
Glioblastoma.
medRxiv
[Preprint]. 2026 Apr 2:2026.03.28.26349013. doi:
10.64898/2026.03.28.26349013. PMID:
41959823. Trial
registration ID: NCT06805305. ˍ